23 and Everyone

By Atom Bergstrom

Atom’s Blog

How do you finance universal genome and exosome testing on humans while simultaneously eliminating animal testing?

Develop an mRNA “vaccine” platform and a deep nasal swab to collect before-and-after results for bioengineering everyone on Earth into “transhuman resources” — the next step beyond “human resources.”

The “vaccine” is the secondary sleight of hand to take the attention off the primary data collection with the swab.

The digital dictatorship’s planetary data colonialism is designed to refashion humans into lab rats for eugenic objectives — 23 and Everyone — without (almost) anyone having a clue in a carload about this ubiquitous legerdemain.

<>

The World Economic Forum is NOT governed from faraway Switzerland.

The Great Reset is straight out of Harvard in the good old U.S.A.

<>

According to The Harvard Gazette (Oct. 1, 2019, yes, 2019) …

“Harvard University has established a multi-year research collaboration with the biotech company Moderna, Inc., with the goal of identifying and developing novel therapeutic approaches that could improve the lives of patients with immunological diseases. Additional funding from Moderna to Harvard Medical School (HMS) will establish an initiative at HMS called the Alliance for RNA Therapies for the Modulation of the Immune System (ARTiMIS), which will enable basic science research in the field of immunology using Moderna’s mRNA and nanoparticle delivery technology. The HMS Department of Immunology ihosted a symposium with Moderna to launch the ARTiMIS initiative last week.

“‘Between the ARTiMIS initiative and the broader research collaboration between Moderna and Harvard, we have established a collaborative framework to support continuous innovation in immunology,’ said Isaac Kohlberg, Harvard’s chief technology development officer and senior associate provost. ‘This access to focused funding and technical resources will enable Harvard researchers to make impactful advances in biomedical science, from the generation of basic biological insights to, we hope, the preclinical development of new immunotherapies.'”

According to the same source …

“To further advance insights toward therapeutics, Moderna has also entered into a multi-year research agreement with the university at large, through the Harvard Office of Technology Development. Under this collaboration framework, Moderna will initially provide sponsored research funding of up to $2.45 million in support of a project led by Ulrich von Andrian, the Edward Mallinckrodt Jr. Professor of Immunopathology and Director of the Center for Immune Imaging at HMS. This project aims to use mRNA technologies to study and manipulate the migration of immune cells from blood to tissues.”

<>



'23 and Everyone' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

©Copyright One Radio Network 2019 • All rights reserved. | Site built by RedLotus Austin
The information on this website and talk shows is solely for informational and entertainment purposes. IT IS NOT INTENDED TO PROVIDE MEDICAL ADVICE. Neither the Editors, producers of One Radio Network, Patrick Timpone, their guests or web masters take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading or following the information contained on this website in written or audio form, live or podcasts. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Before undertaking any course of treatment, the reader must seek the advice of their physician or other health care provider and take total responsibility for his or her actions at all times. Patrick Joseph of the family of Timpone, a man...All rights reserved, without recourse.